Business Description
ISIN : US10950A1060
Total Employee Number:
23,500Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.23 | |||||
Equity-to-Asset | 0.34 | |||||
Debt-to-Equity | 1.17 | |||||
Debt-to-EBITDA | 3.92 | |||||
Interest Coverage | 2.94 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 4.62 | |||||
Beneish M-Score | -2.31 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.2 | |||||
3-Year EBITDA Growth Rate | -3 | |||||
3-Year Book Growth Rate | 30.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 39.58 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 15.38 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 29.34 | |||||
9-Day RSI | 36.87 | |||||
14-Day RSI | 40.03 | |||||
3-1 Month Momentum % | -6.29 | |||||
6-1 Month Momentum % | 43.42 | |||||
12-1 Month Momentum % | 120.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.59 | |||||
Quick Ratio | 1.22 | |||||
Cash Ratio | 0.35 | |||||
Days Inventory | 18.64 | |||||
Days Sales Outstanding | 26.56 | |||||
Days Payable | 30.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.9 | |||||
Shareholder Yield % | 2.5 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 12.38 | |||||
Operating Margin % | 3.12 | |||||
Net Margin % | 2.55 | |||||
EBITDA Margin % | 4.24 | |||||
FCF Margin % | 2.78 | |||||
OCF Margin % | 3.5 | |||||
ROE % | 19.33 | |||||
ROA % | 5.98 | |||||
ROIC % | 8.35 | |||||
3-Year ROIIC % | -2.61 | |||||
ROC (Joel Greenblatt) % | 40.65 | |||||
ROCE % | 9.91 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 42.27 | |||||
Forward PE Ratio | 24.84 | |||||
PE Ratio without NRI | 35.38 | |||||
Price-to-Owner-Earnings | 28.3 | |||||
PS Ratio | 0.86 | |||||
PB Ratio | 5.46 | |||||
Price-to-Free-Cash-Flow | 31.16 | |||||
Price-to-Operating-Cash-Flow | 24.74 | |||||
EV-to-EBIT | 29.12 | |||||
EV-to-Forward-EBIT | 23.84 | |||||
EV-to-EBITDA | 21.43 | |||||
EV-to-Forward-EBITDA | 15.1 | |||||
EV-to-Revenue | 0.91 | |||||
EV-to-Forward-Revenue | 0.76 | |||||
EV-to-FCF | 32.68 | |||||
Price-to-GF-Value | 2.01 | |||||
Earnings Yield (Greenblatt) % | 3.43 | |||||
FCF Yield % | 3.56 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BTSG
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
BrightSpring Health Services Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 14,371.598 | ||
| EPS (TTM) ($) | 1.339 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 39.52 | ||
| 14-Day RSI | 40.03 | ||
| 14-Day ATR ($) | 2.536899 | ||
| 20-Day SMA ($) | 59.616 | ||
| 12-1 Month Momentum % | 120.36 | ||
| 52-Week Range ($) | 26.28 - 73.7499 | ||
| Shares Outstanding (Mil) | 197.86 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BrightSpring Health Services Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BrightSpring Health Services Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-26 08:30 | In 162 days | ||
| Annual report for 2026 | 2027-02-26 | In 161 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 161 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-28 08:30 | In 41 days | ||
| Third quarter earnings results for 2026 | 2026-10-28 | In 40 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-31 08:30 | 72.88 (+3.83%) | ||
| Second quarter earnings results for 2026 | 2026-07-31 | 72.88 (+3.83%) | ||
| General meeting for 2026 | 2026-05-21 13:00 | 58.59 (+2.09%) | ||
| First quarter earnings conference call for 2026 | 2026-05-01 08:30 | 47.97 (-0.35%) | ||
| First quarter earnings results for 2026 | 2026-05-01 | 47.97 (-0.35%) |
BrightSpring Health Services Inc Frequently Asked Questions
Guru Commentaries on NAS:BTSG
BrightSpring Health Services operates through two primary segments: Pharmacy Solutions and Provider Services. The company’s specialty pharmacy platform focuses on oncology therapies, where timely delivery of low distribution drugs is critical. BrightSpring added 29 new drugs from 2024-2025, totaling 153 low distribution drugs, with 31% being exclusive distribution arrangements. The upcoming wave of oral oncology generics is expected to drive significant growth, with an estimated $9.8B of branded market revenues converting to generics through 2027. As branded drugs lose exclusivity, BrightSpring is projected to earn 2-3x the gross profit dollars when a drug goes generic, highlighting its strong competitive moat and growth potential.